Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 156

1.

An analysis of the impact of pre-analytical factors on the urine proteome: Sample processing time, temperature, and proteolysis.

Hepburn S, Cairns DA, Jackson D, Craven RA, Riley B, Hutchinson M, Wood S, Smith MW, Thompson D, Banks RE.

Proteomics Clin Appl. 2014 Nov 15. doi: 10.1002/prca.201400079. [Epub ahead of print]

PMID:
25400092
2.

Variation in genomic landscape of clear cell renal cell carcinoma across Europe.

Scelo G, Riazalhosseini Y, Greger L, Letourneau L, Gonzàlez-Porta M, Wozniak MB, Bourgey M, Harnden P, Egevad L, Jackson SM, Karimzadeh M, Arseneault M, Lepage P, How-Kit A, Daunay A, Renault V, Blanché H, Tubacher E, Sehmoun J, Viksna J, Celms E, Opmanis M, Zarins A, Vasudev NS, Seywright M, Abedi-Ardekani B, Carreira C, Selby PJ, Cartledge JJ, Byrnes G, Zavadil J, Su J, Holcatova I, Brisuda A, Zaridze D, Moukeria A, Foretova L, Navratilova M, Mates D, Jinga V, Artemov A, Nedoluzhko A, Mazur A, Rastorguev S, Boulygina E, Heath S, Gut M, Bihoreau MT, Lechner D, Foglio M, Gut IG, Skryabin K, Prokhortchouk E, Cambon-Thomsen A, Rung J, Bourque G, Brennan P, Tost J, Banks RE, Brazma A, Lathrop GM.

Nat Commun. 2014 Oct 29;5:5135. doi: 10.1038/ncomms6135.

PMID:
25351205
3.
4.

The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer.

Backen A, Renehan AG, Clamp AR, Berzuini C, Zhou C, Oza A, Bannoo S, Scherer SJ, Banks RE, Dive C, Jayson GC.

Clin Cancer Res. 2014 Sep 1;20(17):4549-58. doi: 10.1158/1078-0432.CCR-13-3248. Epub 2014 Jun 19.

5.

Suspension trapping (STrap) sample preparation method for bottom-up proteomics analysis.

Zougman A, Selby PJ, Banks RE.

Proteomics. 2014 May;14(9):1006-0. doi: 10.1002/pmic.201300553. Epub 2014 Mar 26.

PMID:
24678027
6.

Biomarkers and response to bevacizumab--response.

Collinson F, Hutchinson M, Craven RA, Cairns DA, Alexandre Z, Wind TC, Gahir N, Messenger MP, Jackson S, Thompson D, Adusei C, Ledermann J, Hall G, Jayson GC, Selby PJ, Banks RE.

Clin Cancer Res. 2014 Feb 15;20(4):1058. doi: 10.1158/1078-0432.CCR-13-3269. No abstract available.

7.

Discovery and validation of urinary biomarkers for detection of renal cell carcinoma.

Frantzi M, Metzger J, Banks RE, Husi H, Klein J, Dakna M, Mullen W, Cartledge JJ, Schanstra JP, Brand K, Kuczyk MA, Mischak H, Vlahou A, Theodorescu D, Merseburger AS.

J Proteomics. 2014 Feb 26;98:44-58. doi: 10.1016/j.jprot.2013.12.010. Epub 2013 Dec 25.

PMID:
24374379
8.

UBE2QL1 is disrupted by a constitutional translocation associated with renal tumor predisposition and is a novel candidate renal tumor suppressor gene.

Wake NC, Ricketts CJ, Morris MR, Prigmore E, Gribble SM, Skytte AB, Brown M, Clarke N, Banks RE, Hodgson S, Turnell AS, Maher ER, Woodward ER.

Hum Mutat. 2013 Dec;34(12):1650-61. doi: 10.1002/humu.22433. Epub 2013 Oct 7.

9.

VHL-dependent regulation of a β-dystroglycan glycoform and glycogene expression in renal cancer.

Aggelis V, Craven RA, Peng J, Harnden P, Schaffer L, Hernandez GE, Head SR, Maher ER, Tonge R, Selby PJ, Banks RE.

Int J Oncol. 2013 Nov;43(5):1368-76. doi: 10.3892/ijo.2013.2066. Epub 2013 Aug 21.

10.

Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection.

Collinson F, Hutchinson M, Craven RA, Cairns DA, Zougman A, Wind TC, Gahir N, Messenger MP, Jackson S, Thompson D, Adusei C, Ledermann JA, Hall G, Jayson GC, Selby PJ, Banks RE.

Clin Cancer Res. 2013 Sep 15;19(18):5227-39. doi: 10.1158/1078-0432.CCR-13-0489. Epub 2013 Aug 9.

11.

Plasma osteopontin concentrations in patients with cutaneous melanoma.

Filia A, Elliott F, Wind T, Field S, Davies J, Kukalizch K, Randerson-Moor J, Harland M, Bishop DT, Banks RE, Newton-Bishop JA.

Oncol Rep. 2013 Oct;30(4):1575-80. doi: 10.3892/or.2013.2666. Epub 2013 Aug 8.

12.

Oncogene-induced cellular senescence elicits an anti-Warburg effect.

Banks RE.

Proteomics. 2013 Sep;13(17):2542-3. doi: 10.1002/pmic.201300335.

PMID:
23922328
13.

Serum aminoacylase-1 is a novel biomarker with potential prognostic utility for long-term outcome in patients with delayed graft function following renal transplantation.

Welberry Smith MP, Zougman A, Cairns DA, Wilson M, Wind T, Wood SL, Thompson D, Messenger MP, Mooney A, Selby PJ, Lewington AJ, Banks RE.

Kidney Int. 2013 Dec;84(6):1214-25. doi: 10.1038/ki.2013.200. Epub 2013 Jun 5.

14.

A comparison of the analytical performance of five commercially available assays for neutrophil gelatinase-associated lipocalin using urine.

Kift RL, Messenger MP, Wind TC, Hepburn S, Wilson M, Thompson D, Smith MW, Sturgeon C, Lewington AJ, Selby PJ, Banks RE.

Ann Clin Biochem. 2013 May;50(Pt 3):236-44. doi: 10.1258/acb.2012.012117.

PMID:
23605129
15.

miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis.

McCormick RI, Blick C, Ragoussis J, Schoedel J, Mole DR, Young AC, Selby PJ, Banks RE, Harris AL.

Br J Cancer. 2013 Mar 19;108(5):1133-42. doi: 10.1038/bjc.2013.56. Epub 2013 Feb 28.

16.

Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers.

Wood SL, Knowles MA, Thompson D, Selby PJ, Banks RE.

Nat Rev Urol. 2013 Apr;10(4):206-18. doi: 10.1038/nrurol.2013.24. Epub 2013 Feb 26. Review.

PMID:
23443013
17.

Proteomics and the search for biomarkers for renal cancer.

Craven RA, Vasudev NS, Banks RE.

Clin Biochem. 2013 Apr;46(6):456-65. doi: 10.1016/j.clinbiochem.2012.11.029. Epub 2012 Dec 7. Review.

PMID:
23228867
18.

Impact of pre-analytical factors on the proteomic analysis of formalin-fixed paraffin-embedded tissue.

Thompson SM, Craven RA, Nirmalan NJ, Harnden P, Selby PJ, Banks RE.

Proteomics Clin Appl. 2013 Apr;7(3-4):241-51. doi: 10.1002/prca.201200086. Epub 2013 Mar 6. Review.

19.

Proteomic analysis of formalin-fixed paraffin-embedded renal tissue samples by label-free MS: assessment of overall technical variability and the impact of block age.

Craven RA, Cairns DA, Zougman A, Harnden P, Selby PJ, Banks RE.

Proteomics Clin Appl. 2013 Apr;7(3-4):273-82. doi: 10.1002/prca.201200065. Epub 2013 Mar 6.

20.

Retinoic acid-induced protein 3: identification and characterisation of a novel prognostic colon cancer biomarker.

Zougman A, Hutchins GG, Cairns DA, Verghese E, Perry SL, Jayne DG, Selby PJ, Banks RE.

Eur J Cancer. 2013 Jan;49(2):531-9. doi: 10.1016/j.ejca.2012.07.031. Epub 2012 Sep 26.

PMID:
23021913
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk